ArticleFrontiers in cell and developmental biology2026
Concurrent expression of glucose-6-phosphate dehydrogenase and secreted phosphoprotein 1 characterizes an aggressive and immunosuppressive tumor state in hepatocellular carcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite improved outcomes with combined hepatic arterial infusion chemotherapy (HAIC) and systemic therapy in hepatocellular carcinoma (HCC), therapeutic resistance is frequently driven by the tumor microenvironment. We aimed to explore biological features associated with therapeutic resistance in HCC. Methods: We integrated single-cell transcriptomics of a therapy-progressive lesion with large-scale bulk transcriptomic modeling and independent clinical validation. We performed immunohistochemistry in an independent retrospective cohort of 114 treatment-naïve patients to clinically validate the computational findings. Results: Single-cell analysis revealed concurrent upregulation of glucose-6-phosphate dehydrogenase (G6PD) and secreted phosphoprotein 1 (SPP1) in tumor hepatocytes from an index therapy-progressive lesion. A metabolic-transcriptional risk signature effectively stratified overall survival in the TCGA-LIHC and ICGC LIRI-JP cohorts. This signature was associated with an "inflamed-yet-suppressed" tumor microenvironment, characterized by concurrent upregulation of multiple immune checkpoints and defective cytotoxic capacity. Exploratory intercellular communication modeling inferred that surviving hepatocytes were major senders of SPP1-related signaling. In the clinical validation cohort, tissue G6PD H-score was significantly associated with shorter recurrence-free survival in univariable analysis (HR = 1.086 per 10-point increase, 95% CI 1.015-1.162, P = 0.017) and exploratory stratified analyses. G6PD was positively correlated with SPP1 at both the bulk transcriptomic and tissue protein levels (protein Spearman r = 0.571, P < 0.0001). Discussion: These findings suggest that concurrent G6PD and SPP1 expression characterizes an aggressive and immunosuppressive tumor state in HCC. Although this association may provide biological insight into treatment refractoriness, its predictive value for modern combination therapies requires prospective validation in treated cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.